Herpesvirus

Vaccine Licensed for Genital Herpes Management

Published in Vaccine Weekly, March 31st, 1997

Cantab Pharmaceuticals plc, Cambridge, Massachusetts, and Glaxo Wellcome plc, London, United Kingdom, announced that the two companies have signed an agreement to develop and market the DISC HSV vaccine for the treatment and prevention of genital herpes.

Genital herpes is a life-long infection characterized by recurrent episodes of the disease. There are approximately 700,000 new cases of genital herpes reported worldwide each year and it is now estimated that one in every five people in the developed world currently carry the genital herpes virus.

Diagnosis of genital herpes has a profound psychological impact on the patient, the burden of which...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1997-03-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry